Updated time: 2020-10-14 11:45:09
10A-1090915
2020-10-14
US Provisional Patent Application
Mouse monoclonal antibodies (mAbs) were generated against the receptor-binding domain (RBD) domain of the SARS-CoV-2 spike (S) protein by the hybridoma technique. The neutralizing and protective activities of these mAbs were assessed using ELISA, flow cytometry, a plaque reduction neutralization test (PRNT), and SARS-CoV-2-infected mice. The binding epitopes were determined for twelve chimeric neutralizing anti-SARS-CoV-2 RBD mAbs, and the neutralizing activities were assessed in vivo to evaluate their therapeutic potential.
We developed six chAbs with high neutralizing potency. Then, using site-directed mutagenesis of ACE2 binding residues in RBD, we have identified the epitopes of six chimeric therapeutic antibodies. A cocktail of therapeutic chAbs that target three separate epitopes on the RBM of SARS-CoV-2 spike protein may increase therapeutic efficacy and decrease the potential for virus escape mutants, serving to benefit a wide range of COVID-19 patients.
- Antibodies are highly specific and sensitive.
- Anti-spike antibodies have neutralizing effects for therapy.
- A cocktail of therapeutic antibodies can improve the efficacy of COVID-19 treatment and avoid virus escape mutants.
- To develop SARS-CoV-2 rapid diagnosis kit.
- To develop SARS-CoV-2 therapeutic antibodies.
Han-Chung Wu、Yi-Ling Lin、Mi-Hua Tao
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Potent Neutralizing Antibodies for Prevention and Treatment of COVID-19